Author:
Chen Zigui,Yan Xin,Miao Changfeng,Liu Longyang,Liu Su,Xia Ying,Fang Weiyi,Zheng Dandan,Luo Qisheng
Abstract
AbstractMyosin heavy chain 9 (MYH9) plays an important role in a number of diseases. Nevertheless, the function of MYH9 in glioma is unclear. The present research aimed to investigate the role of MYH9 in glioma and determine whether MYH9 is involved in the temozolomide chemoresistance of glioma cells. Our results showed that MYH9 increased the proliferation and temozolomide resistance of glioma cells. The mechanistic experiments showed that the binding of MYH9 to NAP1L1, a potential promoter of tumor proliferation, inhibited the ubiquitination and degradation of NAP1L1 by recruiting USP14. Upregulation of NAP1L1 increased its binding with c-Myc and activated c-Myc, which induced the expression of CCND1/CDK4, promoting glioma cell temozolomide resistance and proliferation. Additionally, we found that MYH9 upregulation was strongly related to patient survival and is therefore a negative factor for patients with glioma. Altogether, our results show that MYH9 plays a role in glioma progression by regulating NAP1L1 deubiquitination. Thus, targeting MYH9 is a potential therapeutic strategy for the clinical treatment of glioma in the future.
Funder
President Foundation of Integrated Hospital of Traditional Chinese Medicine, Southern Medical University
Haikou People’s Hospital to introduce high-level talent project in 2022
Natural Science Foundation of Guangxi Province
The First Batch of High-level Talent Scientific Research Projects of the Affiliated Hospital of Youjiang Medical University for Nationalities in 2019
Natural Science Foundation of Guangxi Zhuang Autonomous Region
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference35 articles.
1. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G, Glioma. Nat Rev Dis Primers. 2015;07:161.
2. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25(26).
3. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 2020 07;70(4).
4. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10:778–90.
5. Pecci A, Ma X, Savoia A, Adelstein RS. MYH9: structure, functions and role of nonmuscle myosin IIA in human disease. Gene. 2018;664:152–67.